Cancer

Views & Analysis

Secondary-effects-of-COVID-19-on-the-pharma-healthcare-and-patients

Secondary effects of COVID-19 on pharma, healthcare and pati...

Reminders of the impact of the COVID-19 pandemic on our healthcare system, economy, and day-to-day lives are everywhere.

News

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

News

Roche's Tecentriq gains new first-line lung cancer use

Roche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients.

News

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer.

News

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received the

News

Roche's TIGIT drug shows promise in untreated lung cancer

Roche has announced positive first phase 2 results from its new kind of cancer immunotherapy, showing that adding tiragolumab to its already approved Tecentriq creates a more potent combina

Secondary effects of COVID-19 on pharma, healthcare and pati...

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

Roche's Tecentriq gains new first-line lung cancer use

Clovis steals march on AZ with PARP prostate approval

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

Roche's TIGIT drug shows promise in untreated lung cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Cancer

Editor's Picks